
CLAIMS

1. Use of a polymeric composition in the manufacture of a medicament to treat one or more symptoms of a SHC-1/p66-related disease selected from the group consisting ofage-related motor deficits and reduced stride length,

wherein the polymeric composition comprises monomer units having formula I and/or a pharmaceutically acceptable salt or solvate thereof:



Formula I

[in Formula I, each of R_1, R_2, R_3, $R_7$and R_8, independently, is H; R_4 is H or OH, R_5 is OH, R_6 is H, OH, or OCH], and

wherein the polymerized number of the monomer ranges from 2-30, and the average molecular weight of the polymer ranges from 600-10,000.

2. The use of claim 1, wherein the composition is to be administered parenterally, orally, nasally, rectally, topically, or buccally.

3. The use of claim 1, wherein the composition is to be administered at a dose from 50 to 1,500 mg/kg/day.